Advanced Oncotherapy PLC Exercise of Warrants and Issue of Equity (7823M)
23 September 2021 - 8:27PM
UK Regulatory
TIDMAVO
RNS Number : 7823M
Advanced Oncotherapy PLC
23 September 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Exercise of Warrants and Issue of Equity
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that it has received an exercise notice in respect of
warrants (issued in July 2017) to subscribe for 300,000 new
ordinary shares of 25 pence in the Company ("New Ordinary Shares"),
with an exercise price of 25 pence per share.
Once issued, the New Ordinary Shares will rank pari passu in all
respects with the existing Ordinary Shares of the Company.
Application has been made for the 300,000 New Ordinary Shares to
be admitted to trading on AIM ("Admission") and it is expected that
Admission will occur on or around 28 September 2021.
Total voting rights
Following Admission, the Company's enlarged issued share capital
will comprise 439,489,371 Ordinary Shares of 25 pence each, with
one voting right per share ("Ordinary Shares"). The Company does
not hold any ordinary shares in treasury and therefore the total
number of Ordinary Shares with voting rights in the Company will be
439,489,371 .
The above figure of 439,489,371 includes the shares which are
expected to be admitted to trading on or around 24 September 2021,
details of which were announced on 20 September 2021. As also
announced on 20 September 2021, a further 11,145,405 Ordinary
Shares are expected to be admitted to trading on or around 22
October 2021. Accordingly, the total number of shares issued and
admitted to trading on 22 October 2021 will be 450,634,776 Ordinary
Shares, assuming no changes to issued share capital in the
meantime.
The a forementioned figures may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales & Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOELJMMTMTTTBAB
(END) Dow Jones Newswires
September 23, 2021 06:27 ET (10:27 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024